High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
about
Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breastPI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.Next generation sequencing of the nidus of early (adenosquamous proliferation rich) radial sclerosing lesions of the breast reveals evidence for a neoplastic precursor lesion.Recurrent inflammatory myofibroblastic tumors harboring PIK3CA and KIT mutations.MET receptor sequence variants R970C and T992I lack transforming capacity.GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method.Discovery and development of small molecule SHIP phosphatase modulators.Elevated PI3K signaling drives multiple breast cancer subtypes.Therapeutic potential of SH2 domain-containing inositol-5'-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancerAKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomasTargeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation.Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profilePrognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancerCombination of hearing screening and genetic screening for deafness-susceptibility genes in newborns.Pathological criteria and practical issues in papillary lesions of the breast - a review.Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil.Differential effects of AKT1(p.E17K) expression on human mammary luminal epithelial and myoepithelial cells.Frequent PIK3CA activating mutations in nipple adenomas.Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.Differential CD133 expression distinguishes malignant from benign papillary lesions of the breast.Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.Subareolar Sclerosing Ductal Hyperplasia.AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth.Breast Tumor Resembling Tall Cell Variant of Papillary Thyroid Carcinoma: A Solid Papillary Neoplasm With Characteristic Immunohistochemical Profile and Few Recurrent Mutations.Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions.Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions.
P2860
Q28083103-1D49EB7C-D56F-4B34-9B66-7252D00B55D5Q33587930-2D6DB7DD-9F41-4329-9AA7-FDCB03AA6652Q33593888-BAA0C577-7875-42E2-9AD8-27A31FDCA077Q34028920-B6BB6CC1-4DA0-4D6F-8AF2-91BD92475C96Q34033952-68EC099E-D3B4-4B27-9974-DB8D92DA34C9Q34066386-E0A3356A-FF4A-4475-A35F-19936FDAF699Q34084868-6A4A0F13-E22E-4906-94F0-786A4F22EF06Q35058356-4D6BB58E-89B7-49B1-881B-F0E7BF08AD51Q35640263-6BE46505-5648-4A6A-B89F-654BBC0D5FCCQ35718988-9960A02E-FA8E-45ED-AA7D-A59CE05E6BD3Q36101969-EF0E6AE5-AF15-433A-8DC9-0856993810D1Q36209975-914E3AB0-C2CA-4E59-8D17-29CFE5DD6E60Q36228558-803E0326-B39B-4ADC-8BE2-2A031DA63925Q36906305-B7D3E5C5-B6A3-4355-83F2-4D814A03CD44Q37119308-2A58561D-5D74-4630-8BAE-B604D8701E4EQ37162623-E1F0C7D4-3556-42C7-AFC3-7A0AAE0CF982Q37388251-A22C1646-0493-4217-B2FE-5E42AA2E232EQ38696782-6CE01517-006B-44AA-9E40-3E324C71252FQ38702479-AD93D7A4-79EC-4DC4-B5B3-F62CC12A4F78Q39364492-1A0B9C2D-669B-4AC5-A529-DCA962FF7ABFQ39577466-522B8BB8-CCD7-4CC5-B8D3-3F9547202D99Q39580452-2CA40FCF-62CE-443D-AECD-0E97FD5E6E99Q44473846-8D803E19-2B10-487F-9850-6F6B7F3C87D7Q46260717-C195E1B0-C0D5-466D-980F-31F501AF257CQ47950995-6DA05E87-26F3-4529-9D6C-8AD6F16D6603Q50062973-D3E2CB55-13F7-49A6-80DB-1ED29F257FD3Q51072237-2884A1B9-B5DC-4CF9-80F1-94C9FE2DD2D6Q53272132-A3DB5515-C37C-44BE-813A-4DAC5B9AB5E8Q54399355-0806F7B4-F13D-46E8-A2F6-EB02079309B8
P2860
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@ast
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@en
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@nl
type
label
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@ast
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@en
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@nl
prefLabel
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@ast
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@en
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@nl
P2093
P2860
P1433
P1476
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
@en
P2093
Ajia Presnell
Andrea Warrick
Arielle Shukla
Carol Beadling
Christopher L Corless
Jennifer Dunlap
Judith Levine
Megan L Troxell
Neal R Olson
P2860
P2888
P356
10.1038/MODPATHOL.2009.142
P577
2009-11-06T00:00:00Z
P5875
P6179
1037538367